A new study tested whether nalmefene, a drug that blocks certain opioid effects, could prevent a common side effect of the anesthetic sufentanil: sudden, intense coughing. The study included 249 children aged 1 to 6 years who were having elective laparoscopic surgery. All children received sufentanil, and then they were given either a placebo (normal saline) or one of three doses of nalmefene (0.025, 0.05, or 0.1 micrograms per kilogram).
The main finding was that nalmefene reduced the incidence of sufentanil-induced cough (SIC) in a dose-dependent way. In the placebo group, 45.9% of children coughed within one minute of receiving sufentanil. With the highest nalmefene dose (0.1 mcg/kg), only 11.3% coughed. The differences between the highest dose and placebo, and between the highest and lowest dose, were statistically significant.
No safety concerns were reported in the study summary, but the researchers did not provide details on side effects or how well the children tolerated the medication. This is a single randomized trial, and more research is needed to confirm the results and to determine the best dose. The study was designed to find the median effective dose (ED50) of nalmefene for preventing cough in this age group.
For parents and doctors, this finding suggests that nalmefene might be a useful option to prevent coughing during anesthesia in young children. However, the exact dose is still being worked out, and the study did not report on long-term outcomes or safety in larger groups. Always discuss any concerns about anesthesia with your child's medical team.
